Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 272

1.

Exploring the Patterns of Use and Acceptability of Mobile Phones Among People Living With HIV to Improve Care and Treatment: Cross-Sectional Study in Three Francophone West African Countries.

Lepère P, Touré Y, Bitty-Anderson AM, Boni SP, Anago G, Tchounga B, Touré P, Minga A, Messou E, Kanga G, Koule S, Poda A, Calmy A, Ekouevi DK, Coffie PA.

JMIR Mhealth Uhealth. 2019 Nov 13;7(11):e13741. doi: 10.2196/13741.

2.

Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients.

Olearo F, Nguyen H, Bonnet F, Yerly S, Wandeler G, Stoeckle M, Cavassini M, Scherrer A, Costagiola D, Schmid P, Günthard HF, Bernasconi E, Boeni J, D'arminio Monforte A, Zazzi M, Rossetti B, Neau D, Bellecave P, Rijnders B, Reiss P, Wit F, Kouyos R, Calmy A.

Open Forum Infect Dis. 2019 Jul 12;6(10):ofz330. doi: 10.1093/ofid/ofz330. eCollection 2019 Oct.

3.

Next-Generation Sequencing for the Diagnosis of Challenging Culture-Negative Endocarditis.

Kolb M, Lazarevic V, Emonet S, Calmy A, Girard M, Gaïa N, Charretier Y, Cherkaoui A, Keller P, Huber C, Schrenzel J.

Front Med (Lausanne). 2019 Sep 20;6:203. doi: 10.3389/fmed.2019.00203. eCollection 2019.

4.

Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort.

Surial B, Cavassini M, Calmy A, Fehr J, Stöckle M, Bernasconi E, Roth B, Fux CA, Kovari H, Furrer H, Rauch A, Wandeler G; Swiss HIV Cohort Study.

BMC Infect Dis. 2019 Oct 10;19(1):834. doi: 10.1186/s12879-019-4454-9.

5.

The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: baseline participant profile.

Métral M, Darling K, Locatelli I, Nadin I, Santos G, Brugger P, Kovari H, Cusini A, Gutbrod K, Tarr PE, Calmy A, Lecompte TD, Assal F, Monsch A, Kunze U, Stoeckle M, Schwind M, Schmid P, Pignatti R, Di Benedetto C, Du Pasquier R, Cavassini M; NAMACO study group; Swiss HIV Cohort Study.

HIV Med. 2019 Oct 7. doi: 10.1111/hiv.12795. [Epub ahead of print]

6.

Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017.

Ruffieux Y, Lemsalu L, Aebi-Popp K, Calmy A, Cavassini M, Fux CA, Günthard HF, Marzolini C, Scherrer A, Vernazza P, Keiser O, Egger M; Swiss HIV Cohort Study and the Swiss National Cohort.

J Int AIDS Soc. 2019 Aug;22(8):e25339. doi: 10.1002/jia2.25339.

7.

Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.

NAMSAL ANRS 12313 Study Group, Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S, Peeters M, Calmy A, Delaporte E.

N Engl J Med. 2019 Aug 29;381(9):816-826. doi: 10.1056/NEJMoa1904340. Epub 2019 Jul 24.

PMID:
31339676
8.

Cross-Sectional and Cumulative Longitudinal Central Nervous System Penetration Effectiveness Scores Are Not Associated With Neurocognitive Impairment in a Well Treated Aging Human Immunodeficiency Virus-Positive Population in Switzerland.

Santos GMA, Locatelli I, Métral M, Calmy A, Lecompte TD, Nadin I, Hauser C, Cusini A, Hasse B, Kovari H, Tarr P, Stoeckle M, Fux C, Di Benedetto C, Schmid P, Darling KEA, Du Pasquier R, Cavassini M; Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) Study Group.

Open Forum Infect Dis. 2019 Jul 8;6(7):ofz277. doi: 10.1093/ofid/ofz277. eCollection 2019 Jul.

10.

Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence.

Courlet P, Decosterd LA, Brown JA, Alves Saldanha S, Marzolini C, Cavassini M, Stoeckle M, Csajka C, Labhardt ND, Calmy A; Swiss HIV Cohort Study .

J Antimicrob Chemother. 2019 Aug 1;74(8):2468-2470. doi: 10.1093/jac/dkz181. No abstract available.

PMID:
31065722
11.

Why do sub-Saharan Africans present late for HIV care in Switzerland?

Hachfeld A, Darling K, Calmy A, Ledergerber B, Weber R, Battegay M, Wissel K, Di Benedetto C, Fux CA, Tarr PE, Kouyos R, Ruggia LS, Furrer HJ, Wandeler G; Swiss HIV Cohort Study.

HIV Med. 2019 Jul;20(6):418-423. doi: 10.1111/hiv.12727. Epub 2019 May 6.

PMID:
31062497
12.

Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis.

Wandeler G, Buzzi M, Anderegg N, Sculier D, Béguelin C, Egger M, Calmy A.

Version 2. F1000Res. 2018 Aug 30 [revised 2019 Jan 1];7:1359. doi: 10.12688/f1000research.15995.2. eCollection 2018.

13.

The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study.

Young J, Scherrer AU, Calmy A, Tarr PE, Bernasconi E, Cavassini M, Hachfeld A, Vernazza P, Günthard HF, Bucher HC; Swiss HIV Cohort Study.

Antivir Ther. 2019;24(5):343-353. doi: 10.3851/IMP3310.

PMID:
30985290
14.

Antiretroviral Drugs Associated with Subclinical Coronary Artery Disease in the Swiss HIV Cohort Study.

Kovari H, Calmy A, Doco-Lecompte T, Nkoulou R, Marzel A, Weber R, Kaufmann PA, Buechel RR, Ledergerber B, Tarr PE; Swiss HIV Cohort Study.

Clin Infect Dis. 2019 Apr 8. pii: ciz283. doi: 10.1093/cid/ciz283. [Epub ahead of print]

PMID:
30958888
15.

Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patients.

Abela IA, Scherrer AU, Böni J, Yerly S, Klimkait T, Perreau M, Hirsch HH, Furrer H, Calmy A, Schmid P, Cavassini M, Bernasconi E, Günthard HF; Swiss HIV Cohort Study.

Clin Infect Dis. 2019 Mar 7. pii: ciz178. doi: 10.1093/cid/ciz178. [Epub ahead of print]

PMID:
30843028
16.

A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases.

Kusejko K, Bachmann N, Chaudron SE, Nguyen H, Braun DL, Hampel B, Battegay M, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Böni J, Yerly S, Klimkait T, Perreau M, Rauch A, Günthard HF, Kouyos RD; Swiss HIV Cohort Study .

J Infect Dis. 2019 Jun 19;220(2):244-253. doi: 10.1093/infdis/jiz093.

PMID:
30835292
17.

Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection.

Carlisle LA, Turk T, Kusejko K, Metzner KJ, Leemann C, Schenkel CD, Bachmann N, Posada S, Beerenwinkel N, Böni J, Yerly S, Klimkait T, Perreau M, Braun DL, Rauch A, Calmy A, Cavassini M, Battegay M, Vernazza P, Bernasconi E, Günthard HF, Kouyos RD; Swiss HIV Cohort Study .

J Infect Dis. 2019 Jun 19;220(2):254-265. doi: 10.1093/infdis/jiz094.

PMID:
30835266
18.

Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naïve of statin therapy: A cross-sectional analysis from the Swiss HIV cohort.

Gencer B, Pagano S, Vuilleumier N, Satta N, Delhumeau-Cartier C, Meier C, Bavamian S, Montecucco F, Mach F, Calmy A.

Atherosclerosis. 2019 May;284:253-259. doi: 10.1016/j.atherosclerosis.2019.02.015. Epub 2019 Feb 20.

PMID:
30827714
19.

Female Genital Schistosomiasis and HIV: Research Urgently Needed to Improve Understanding of the Health Impacts of This Important Coinfection.

OʼBrien DP, Ford N, Djirmay AG, Calmy A, Vitoria M, Jensen TO, Christinet V.

J Acquir Immune Defic Syndr. 2019 Apr 15;80(5):489-493. doi: 10.1097/QAI.0000000000001957.

PMID:
30730357
20.

[Diagnosis, prevention and treatment of HIV : what's new in 2018 ?]

D'Incau S, Viala B, Ciuffi A, Cavassini M, Calmy A.

Rev Med Suisse. 2019 Jan 9;15(N° 632-633):107-112. Review. French.

PMID:
30629381
21.

Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis.

Biver E, Calmy A, Aubry-Rozier B, Birkhäuser M, Bischoff-Ferrari HA, Ferrari S, Frey D, Kressig RW, Lamy O, Lippuner K, Suhm N, Meier C.

Osteoporos Int. 2019 May;30(5):1125-1135. doi: 10.1007/s00198-018-4794-0. Epub 2019 Jan 2.

PMID:
30603840
22.

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study.

Phillips AN, Venter F, Havlir D, Pozniak A, Kuritzkes D, Wensing A, Lundgren JD, De Luca A, Pillay D, Mellors J, Cambiano V, Bansi-Matharu L, Nakagawa F, Kalua T, Jahn A, Apollo T, Mugurungi O, Clayden P, Gupta RK, Barnabas R, Revill P, Cohn J, Bertagnolio S, Calmy A.

Lancet HIV. 2019 Feb;6(2):e116-e127. doi: 10.1016/S2352-3018(18)30317-5. Epub 2018 Nov 29.

23.

Extracavitary primary effusion lymphoma (PEL) presenting as bilateral adrenal gland involvement in an HIV-positive patient.

Nabergoj M, Nawej Tshikung O, Tsopra O, Ghinescu A, Samii K, Calmy A.

Ann Hematol. 2019 May;98(5):1317-1318. doi: 10.1007/s00277-018-3511-6. Epub 2018 Oct 17. No abstract available.

PMID:
30328487
24.

Anti-inflammatory therapy in well controlled HIV infection.

Tarr PE, Calmy A.

Lancet HIV. 2018 Oct;5(10):e538-e539. doi: 10.1016/S2352-3018(18)30250-9. Epub 2018 Sep 23. No abstract available.

PMID:
30257801
25.

Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study.

Kusejko K, Kadelka C, Marzel A, Battegay M, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Böni J, Yerly S, Klimkait T, Perreau M, Rauch A, Günthard HF, Kouyos RD; Swiss HIV Cohort Study .

Virus Evol. 2018 Sep 18;4(2):vey024. doi: 10.1093/ve/vey024. eCollection 2018 Jul. Review.

26.

Tracing HIV-1 strains that imprint broadly neutralizing antibody responses.

Kouyos RD, Rusert P, Kadelka C, Huber M, Marzel A, Ebner H, Schanz M, Liechti T, Friedrich N, Braun DL, Scherrer AU, Weber J, Uhr T, Baumann NS, Leemann C, Kuster H, Chave JP, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Metzner KJ, Günthard HF, Trkola A; Swiss HIV Cohort Study.

Nature. 2018 Sep;561(7723):406-410. doi: 10.1038/s41586-018-0517-0. Epub 2018 Sep 10.

PMID:
30202088
27.

Lipodystrophy Increases the Risk of CKD Development in HIV-Positive Patients in Switzerland: The LIPOKID Study.

Bouatou Y, Gayet Ageron A, Bernasconi E, Battegay M, Hoffmann M, Staehelin C, Merz L, Kovari H, Fux C, de Seigneux S, Calmy A; Swiss HIV Cohort Study.

Kidney Int Rep. 2018 May 8;3(5):1089-1099. doi: 10.1016/j.ekir.2018.04.014. eCollection 2018 Sep.

28.

A buyers' club to improve access to hepatitis C treatment for vulnerable populations.

Vernaz N, Calmy A, Hurst S, Jackson Y, Negro F, Perrier A, Wolff H.

Swiss Med Wkly. 2018 Aug 22;148:w14649. doi: smw.2018.14649. eCollection 2018 Aug 13.

29.

Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort.

Pelchen-Matthews A, Ryom L, Borges ÁH, Edwards S, Duvivier C, Stephan C, Sambatakou H, Maciejewska K, Portu JJ, Weber J, Degen O, Calmy A, Reikvam DH, Jevtovic D, Wiese L, Smidt J, Smiatacz T, Hassoun G, Kuznetsova A, Clotet B, Lundgren J, Mocroft A; EuroSIDA study.

AIDS. 2018 Oct 23;32(16):2405-2416. doi: 10.1097/QAD.0000000000001967.

PMID:
30134296
30.

Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in Switzerland.

Kusejko K, Marzel A, Hampel B, Bachmann N, Nguyen H, Fehr J, Braun DL, Battegay M, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Böni J, Yerly S, Klimkait T, Perreau M, Rauch A, Günthard HF, Kouyos RD; Swiss HIV Cohort Study.

HIV Med. 2018 Nov;19(10):688-697. doi: 10.1111/hiv.12660. Epub 2018 Jul 26.

PMID:
30051600
31.

Expert consensus statement on the science of HIV in the context of criminal law.

Barré-Sinoussi F, Abdool Karim SS, Albert J, Bekker LG, Beyrer C, Cahn P, Calmy A, Grinsztejn B, Grulich A, Kamarulzaman A, Kumarasamy N, Loutfy MR, El Filali KM, Mboup S, Montaner JS, Munderi P, Pokrovsky V, Vandamme AM, Young B, Godfrey-Faussett P.

J Int AIDS Soc. 2018 Jul;21(7):e25161. doi: 10.1002/jia2.25161.

32.

Cost Estimates for Human Immunodeficiency Virus (HIV) Care and Patient Characteristics for Health Resource Use From Linkage of Claims Data With the Swiss HIV Cohort Study.

Leon-Reyes S, Schäfer J, Früh M, Schwenkglenks M, Reich O, Schmidlin K, Staehelin C, Battegay M, Cavassini M, Hasse B, Bernasconi E, Calmy A, Hoffmann M, Schoeni-Affolter F, Zhao H, Bucher HC.

Clin Infect Dis. 2019 Feb 15;68(5):827-833. doi: 10.1093/cid/ciy564.

33.

Stable HIV-1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study.

Sculier D, Doco-Lecompte T, Yerly S, Metzner KJ, Decosterd LA, Calmy A.

HIV Med. 2018 Jun 22. doi: 10.1111/hiv.12626. [Epub ahead of print]

34.

Universal test and treat is not associated with sub-optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial.

Iwuji C, McGrath N, Calmy A, Dabis F, Pillay D, Newell ML, Baisley K, Porter K.

J Int AIDS Soc. 2018 Jun;21(6):e25112. doi: 10.1002/jia2.25112.

35.

The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis.

Marzel A, Kusejko K, Weber R, Bruggmann P, Rauch A, Roth JA, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Böni J, Yerly S, Klimkait T, Perreau M, Günthard HF, Kouyos RD; Swiss HIV Cohort Study .

Open Forum Infect Dis. 2018 May 19;5(5):ofy078. doi: 10.1093/ofid/ofy078. eCollection 2018 May.

36.

Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity.

Kadelka C, Liechti T, Ebner H, Schanz M, Rusert P, Friedrich N, Stiegeler E, Braun DL, Huber M, Scherrer AU, Weber J, Uhr T, Kuster H, Misselwitz B, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Kouyos RD, Günthard HF, Trkola A; Swiss HIV Cohort Study.

J Exp Med. 2018 Jun 4;215(6):1589-1608. doi: 10.1084/jem.20180246. Epub 2018 May 24.

37.

Will NNRTIs be driving forward again?

Calmy A, Tarr PE.

Lancet HIV. 2018 May;5(5):e200-e201. doi: 10.1016/S2352-3018(18)30037-7. Epub 2018 Mar 25. No abstract available.

PMID:
29592841
38.

Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons.

Tarr PE, Ledergerber B, Calmy A, Doco-Lecompte T, Marzel A, Weber R, Kaufmann PA, Nkoulou R, Buechel RR, Kovari H; Swiss HIV Cohort Study.

Eur Heart J. 2018 Jun 14;39(23):2147-2154. doi: 10.1093/eurheartj/ehy163.

PMID:
29590332
39.

Managing Advanced HIV Disease in a Public Health Approach.

Ford N, Meintjes G, Calmy A, Bygrave H, Migone C, Vitoria M, Penazzato M, Vojnov L, Doherty M; Guideline Development Group for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy.

Clin Infect Dis. 2018 Mar 4;66(suppl_2):S106-SS110. doi: 10.1093/cid/cix1139.

40.

The Persistent Challenge of Advanced HIV Disease and AIDS in the Era of Antiretroviral Therapy.

Calmy A, Ford N, Meintjes G.

Clin Infect Dis. 2018 Mar 4;66(suppl_2):S103-SS105. doi: 10.1093/cid/cix1138. No abstract available.

41.

Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites.

Marsousi N, Daali Y, Fontana P, Reny JL, Ancrenaz-Sirot V, Calmy A, Rudaz S, Desmeules JA, Samer CF.

Clin Pharmacokinet. 2018 Oct;57(10):1347-1354. doi: 10.1007/s40262-018-0637-6.

PMID:
29453687
42.

Evaluation of the Xpert MTB/RIF assay for the diagnosis of smear-negative pulmonary and extrapulmonary tuberculosis in Madagascar.

Rakotoarivelo R, Ambrosioni J, Rasolofo V, Raberahona M, Rakotosamimanana N, Andrianasolo R, Ramanampamonjy R, Tiaray M, Razafimahefa J, Rakotoson J, Randria M, Bonnet F, Calmy A; MadaXpert Study Group.

Int J Infect Dis. 2018 Apr;69:20-25. doi: 10.1016/j.ijid.2018.01.017. Epub 2018 Mar 1.

43.

[Antiretroviral treatments : towards simplified regimens ?]

Nawej Tshikung O, Calmy A.

Rev Med Suisse. 2018 Jan 10;14(588-589):102-106. French.

PMID:
29337462
44.

Neglect of attention to reproductive health in women with HIV infection: contraceptive use and unintended pregnancies in the Swiss HIV Cohort Study.

Aebi-Popp K, Mercanti V, Voide C, Nemeth J, Cusini A, Jakopp B, Nicca D, Rasi M, Bruno A, Calmy A, Martinez de Tejada B; Swiss HIV Cohort Study.

HIV Med. 2018 May;19(5):339-346. doi: 10.1111/hiv.12582. Epub 2018 Jan 16.

PMID:
29336516
45.

Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study.

Peters L, Mocroft A, Grint D, Moreno S, Calmy A, Jevtovic D, Sambatakou H, Lacombe K, De Wit S, Rockstroh J, Smidt J, Karpov I, Grzeszczuk A, Haziosmanovic V, Gottfredsson M, Radoi R, Kuzovatova E, Orkin C, Ridolfo AL, Zapirain J, Lundgren J.

Antivir Ther. 2018;23(5):405-413. doi: 10.3851/IMP3218.

PMID:
29303483
46.

Time to overcome pretreatment HIV drug resistance.

Yerly S, Calmy A.

Lancet Infect Dis. 2018 Mar;18(3):239-240. doi: 10.1016/S1473-3099(17)30709-0. Epub 2017 Nov 30. No abstract available.

47.

Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients.

Satta N, Pagano S, Montecucco F, Gencer B; Swiss HIV Cohort Study, Mach F, Kaiser L, Calmy A, Vuilleumier N.

J Infect. 2018 Feb;76(2):186-195. doi: 10.1016/j.jinf.2017.11.008. Epub 2017 Dec 14.

PMID:
29198606
48.

Blinded by Zika? A missed HIV diagnosis that resulted in optic neuropathy and blindness: a case report.

Hirschel T, Steffen H, Pecoul V, Calmy A.

BMC Res Notes. 2017 Dec 1;10(1):664. doi: 10.1186/s13104-017-2970-5.

49.

Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule.

Veit O, Domingo C, Niedrig M, Staehelin C, Sonderegger B, Héquet D, Stoeckle M, Calmy A, Schiffer V, Bernasconi E, Flury D, Hatz C, Zwahlen M, Furrer H; Swiss HIV Cohort Study.

Clin Infect Dis. 2018 Mar 19;66(7):1099-1108. doi: 10.1093/cid/cix960.

PMID:
29140432
50.

Benefits and risks of rapid initiation of antiretroviral therapy.

Ford N, Migone C, Calmy A, Kerschberger B, Kanters S, Nsanzimana S, Mills EJ, Meintjes G, Vitoria M, Doherty M, Shubber Z.

AIDS. 2018 Jan 2;32(1):17-23. doi: 10.1097/QAD.0000000000001671.

Supplemental Content

Support Center